Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Chinese Medical Journal|March 11, 2025
Tissue-resident memory T cells and their function in skin diseasesXibei Chen, Yuxin Zheng, Xiaoyong Man, et al.The World Allergy Organization Journal|January 27, 2025
COVID-19 related epigenetic changes and atopic dermatitis: An exploratory analysisZhenwei Tang, Yu Chen, Yuzhen Ouyang, et al.Heliyon|March 25, 2024
Clinical and laboratory features of neurosyphilis: A single-center, retrospective study of 402 patientsWei Li, Jinfang Sun, Tingting Wang, et al.Molecular and Cellular Biochemistry|September 30, 2010
Regulation of adhesion by vascular endothelial growth factor in HaCaT cellsChunming Li, Xiaoyong Man, Wei Li, et al.Journal of the American Academy of Dermatology|November 26, 2024
A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasisXiaoyong Man, Katya Zaharieva, Grażyna Pulka, et al.Journal of the American Academy of Dermatology|August 10, 2025
A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)Xiaoyong Man, Katya Zaharieva, Grażyna Pulka, et al.Dermatology and Therapy|September 19, 2025
The ChinaSTAD Chinese Registry in Patients with Moderate-To-Severe Atopic Dermatitis Not Controlled by Topical Therapy: Baseline Characteristics, Disease Burden and TreatmentPing Liu, Bingjiang Lin, Yanna Shen, et al.Chinese Medical Journal|December 24, 2025
Developing a simplified assessment scale of severity and simplified criteria for initiating systemic treatment for atopic dermatitis by the Delphi methodLi Zhang, Shengxin Cao, Yangfeng Ding, et al.The Journal of Dermatological Treatment|July 13, 2026
Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter studyYu Wang, Chengzhi Lv, Bin Yang, et al.The British Journal of Dermatology|March 16, 2026
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot studyXu Yao, Yi Liu, Yang Luo, et al.Pageof 3